Supernus Pharmaceuticals (SUPN) Rating Reiterated by B. Riley

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reissued by research analysts at B. Riley in a research note issued to investors on Thursday. They currently have a $54.00 price objective on the specialty pharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 16.13% from the company’s previous close.

SUPN has been the topic of a number of other research reports. SunTrust Banks reaffirmed a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Janney Montgomery Scott reaffirmed a “hold” rating and set a $47.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Jefferies Group reaffirmed a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average target price of $49.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $46.50 on Thursday. Supernus Pharmaceuticals has a 1-year low of $23.10 and a 1-year high of $50.04. The company has a market cap of $2,191.46, a price-to-earnings ratio of 43.87 and a beta of 1.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company’s revenue for the quarter was up 41.5% compared to the same quarter last year. analysts anticipate that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total transaction of $899,600.00. Following the transaction, the vice president now owns 32,500 shares in the company, valued at $1,461,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Victor Vaughn sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at approximately $1,023,421.76. The disclosure for this sale can be found here. Insiders have sold 145,750 shares of company stock worth $6,173,173 in the last quarter. Company insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. Vanguard Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 438.7% in the third quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after purchasing an additional 400,083 shares during the last quarter. Scout Investments Inc. grew its holdings in shares of Supernus Pharmaceuticals by 239.5% in the third quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock worth $22,636,000 after purchasing an additional 399,225 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Supernus Pharmaceuticals in the third quarter worth about $10,646,000. Finally, Royal Bank of Canada grew its holdings in shares of Supernus Pharmaceuticals by 790.8% in the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after purchasing an additional 240,978 shares during the last quarter. Hedge funds and other institutional investors own 98.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/01/18/supernus-pharmaceuticals-supn-rating-reiterated-by-b-riley.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply